Adverse Reactions of Four Multi-Targeted Tyrosine Kinase Inhibitors: A Descriptive Analysis of the WHO-VigiAccess Database [PDF]
Frontiers in PharmacologyBackgroundThe introduction of multi-targeted tyrosine kinase inhibitors (MTKIs) such as axitinib, lenvatinib, sorafenib, and sunitinib has greatly broadened the available treatment options for Renal Cell Carcinoma (RCC).
Xuefan Zeng
exaly +8 more sources
A Real-World Data Analysis of Ocular Adverse Events Linked to Anti-VEGF Drugs: A WHO-VigiAccess Study [PDF]
Frontiers in PharmacologyIntroductionVascular endothelial growth factor (VEGF) is key to wet age-related macular degeneration (wAMD). Anti-VEGF drugs are the main treatment in clinics.
Chen Li +3 more
exaly +8 more sources
Adverse Events of Hepatic Anti-Fibrotic Agents in Phase 3 and Above Clinical Trials: A Descriptive Analysis of the WHO-VigiAccess Database [PDF]
Frontiers in PharmacologyIntroductionLiver fibrosis is a pathological condition in response to chronic liver injuries. Currently, there is no Food and Drug Administration (FDA) approved pharmacotherapy for liver fibrosis.
Yuwei Liu +7 more
exaly +8 more sources
Characterization of adverse reactions to four common targeted drugs for hepatocellular carcinoma in WHO-VigiAccess [PDF]
Scientific ReportsHepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality, with limited therapeutic options available for advanced stages of the disease.
Zeyu Wang, Jiyao Sheng, Xuewen Zhang
doaj +5 more sources
Adverse Reactions of First-Line Tyrosine Kinase Inhibitors in Advanced Hepatocellular Carcinoma Treatment: A Descriptive Analysis From WHO-VigiAccess [PDF]
International Journal of HepatologyConclusion: While gastrointestinal toxicities were class-wide concerns, agent-specific risks necessitate tailored monitoring. These findings emphasized the need for vigilant monitoring and personalized management in clinical practice.
Wei fan Sui +5 more
doaj +5 more sources
Assessing the real-world safety of vutrisiran for transthyretin-mediated amyloidosis with polyneuropathy: Based on WHO-VigiAccess and FAERS databases. [PDF]
PLoS ONEBackgroundVutrisiran is a double-stranded siRNA targeting transthyretin mRNA, primarily for the treatment of transthyretin-mediated amyloidosis (ATTR) with polyneuropathy.
Weiwei Tong +8 more
doaj +3 more sources
The Characteristics of Adverse Reactions of Three Anti-Prostate Cancer Drugs Based on Vigiaccess Database and Bibliometric Analysis [PDF]
Frontiers in PharmacologyBackgroundAndrogen antagonists, including apalutamide, darolutamide, and enzalutamide, play a crucial role in the treatment of prostate cancer.
Liwei Zhang +2 more
exaly +4 more sources
Pharmacovigilance analysis of cutaneous adverse drug reactions for cetuximab, panitumumab, and necitumumab based on EudraVigilance and WHO VigiAccess [PDF]
Frontiers in PharmacologyIntroductionAnti-EGFR monoclonal antibodies (mAbs)--cetuximab, panitumumab, and necitumumab--are cornerstone therapies for selected solid tumors but are frequently associated with cutaneous adverse drug reactions (ADRs).
Natalia Sauer +4 more
doaj +4 more sources
Characterizing ADRs of Enfortumab vedotin and Erdafitinib in bladder cancer treatment: a descriptive analysis from WHO-VigiAccess [PDF]
Frontiers in PharmacologyIntroductionEnfortumab vedotin (EV) and Erdafitinib are effective therapeutic drugs for bladder cancer patients following post-chemotherapy and immunotherapy.
Yuanbin Huang +9 more
doaj +4 more sources
Post-marketing safety signals and report-level ARIA-E stratification for lecanemab and donanemab: an integrated FAERS and WHO-VigiAccess pharmacovigilance study [PDF]
Therapeutic Advances in Drug SafetyBackground: Anti-β-amyloid monoclonal antibodies provide a disease-modifying treatment approach for Alzheimer’s disease, but post-marketing safety concerns remain, particularly amyloid-related imaging abnormalities (ARIA).
Wei-Yang Xue +6 more
doaj +3 more sources